Generalized Anxiety Disorder
Conditions
Interventions
Mind-Regulating Seven-Acupoint Acupuncture Group:Mind-Regulating Seven-Acupoint Acupuncture
Escitalopram Group:Escitalopram
Yin-Yang Regulating Moxibustion Group:Yin-Yang Regulating Moxibustion
Sponsors
Hubei Provincial Hospital of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: (1) Meet diagnostic criteria for Generalized Anxiety Disorder; (2) Stable condition with duration of illness = 6 months; (3) Hamilton Anxiety Rating Scale (HAMA) score = 14; (4) No other anti-anxiety treatment received within the past 1 month; (5) Aged 18–75 years; (6) Provision of written informed consent voluntarily agreeing to participate in the study.
Exclusion criteria
Exclusion criteria: (1) History of other types of psychiatric disorders prior to enrollment such as depressive disorder phobic anxiety disorder panic disorder obsessive-compulsive disorder organic mental disorder schizoaffective disorder dementia bipolar disorder or other types of anxiety disorders; (2) Presence of severe suicidal ideation or history of suicide attempt; (3) Comorbid severe cardiovascular hepatic renal endocrine hematological or other major internal medical diseases;(4) History or current presence of significant traumatic brain injury or organic brain disease; (5) Secondary anxiety due to chronic diseases (e.g. hyperthyroidism heart disease hypertension); (6) Use of anti-anxiety medications antidepressants benzodiazepines or participation in other forms of systemic psychotherapy within the past month; (7) Comorbid alcohol or substance dependence; (8) Allergy or intolerance to study-related interventions (e.g. Escitalopram moxa sticks) or history of allergic constitution; (9) Pregnancy planned pregnancy within 6 months or breastfeeding; (10) Participation in another clinical trial within the past 6 months or current participation; (11) Other reasons deemed by the investigator to preclude cooperation with the trial or likely to affect efficacy or safety assessment (e.g. severe somatization disorder impaired consciousness); (12) Anticipated poor compliance or inability to adhere to follow-up schedule as judged by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hamilton Anxiety Scale (HAMA); | — |
Secondary
| Measure | Time frame |
|---|---|
| Blood Analysis;TCM Symptom Grading and Quantification Scale;Pittsburgh Sleep Quality Index (PSQI); | — |
Countries
China
Contacts
Public ContactFeng Hu
Hubei Provincial Hospital of Traditional Chinese Medicine
Outcome results
None listed